Abstract
Combination pharmaceutical products, or fixed-dose combinations (FDC' s), offer
benefits to many drug classes due to the additive nature of therapeutic effect
and the reduced level of side-effects associated with their use. Their core
advantage however is an improvement in convenience that stems from reducing
prescription numbers and their associated administrative costs. Although
fixed-dose combination drugs have historically attracted disapproval from
physicians, who typically prefer to determine the components and ratios of
drug applications at their own discretion, a widespread acknowledgement and
acceptance of these therapies has now been established. This is largely due to
their effectiveness in areas such as HIV and asthma, but the successful
positioning of combination products remains difficult in therapeutic areas
where combination therapies only provide marginally incremental benefits.
Launching Combination Products is a new report published by Business Insights
that provides detailed strategic guidance for the preparation and successful
execution of combination product launches. This report performs a
comprehensive examination of current competitive pressures, best practices and
future developments in key therapeutic areas including cardiovascular,
respiratory, HIV and women' s health. Detailed case studies also provide unique
insights into the brand extension and franchise development strategies of
leading companies and help to identify the key success factors behind recent
combination product launches. Discover potential growth opportunities for your
brands, identify future combination launches and use case studies to
understand the most effective launch strategies across key therapeutic areas
with this new report.
View Cart
